Innovation and Knowledge Centre Regenerative Therapies and Devices Tranche 2 IKC RTD

再生疗法和设备创新和知识中心建立了一个可持续的平台，以解决再生疗法和设备新技术的创造问题。通过战略优先级和关键技术领域的发展，我们力求在成本限制日益增加的复杂全球市场中，以更高的可靠性促进它们的加速采用。促进身体组织再生的疗法和设备提供了彻底改变医疗保健的潜力，并成为经济增长的催化剂，在医疗保健技术领域创造了一个新的商业领域。通过开发新的创新基础设施和实践，IKCRTD建立在大学及其合作伙伴（行业，NHS和中介/用户）的文化和研究景观之上，这些基础设施和实践提供了主要的临床，健康和行业成果。在运营的头两年里，IKCRTD建立了一个高质量的研究和创新平台，该平台的基础是：8500万英镑的新研究收入建立了学术供应链，拥有250名研究人员的新研究中心大学投资了一个新的医疗技术创新大楼，以创建一个促进创新的社区。通过以下方式实现成功的可持续创新：开发强大的可持续发展模式对关键市场部门进行战略识别和优先排序，促进35种新产品的开发，这些新产品已经进入市场，在学术、行业和临床合作伙伴关系中建立创新文化。通过重要的政治访问和媒体报道建立了重要的形象和声誉：通过与Regener8的战略结盟扩大了在英国的影响力和联系建立了一个医疗技术品牌，以促进公司，学者和临床合作伙伴与该中心的合作。建立强大的创新管理：招募并建立核心团队，建立治理结构建立创新管道，阶段大门和项目进展标准一个明确的知识产权组合，11个概念验证和4个共同开发项目直接资助107个协同创新项目的管道与34家公司合作伙伴接触200多家潜在合作公司的更广泛网络。

The Innovation and Knowledge Centre in Regenerative Therapies and Devices has established a sustainable platform to address the creation of new technologies in Regenerative Therapies and Devices. Through strategic prioritisation and development of key technology areas we have sought to promote their accelerated adoption, with increased reliability, within a complex global marketplace with increasing cost constraints. Therapies and devices which facilitate the regeneration of body tissues offer the potential to revolutionise healthcare and be a catalyst for economic growth, creating a new business sector within healthcare technology. The IKCRTD has built upon the culture and research landscape of the University and its partners (industry, NHS and intermediaries/users) through the development of new innovation infrastructure and practices which deliver major clinical, health and industry outcomes.In the first two years of operation IKCRTD has:Established a high quality research and innovation platform that is underpinned by: £85m new research income Established academic supply chain, new research centre with 250 researchers University investment for a new Medical Technologies Innovation building to create a community to stimulate innovation.Embedded successful sustainable innovation through: The development of a robust sustainability model Strategic identification and prioritisation of key market sectors Contributing to the development of 35 new products that have reached the market Developing a culture of innovation across academic, industry and clinical partnerships.Established a significant profile and reputation through: Significant political visits and media coverage Widened reach and connections across the UK through strategic alignment with Regener8 Established a Medical Technologies brand to facilitate companies, academics and clinical partners to collaborate with the centre.Established robust innovation management through: Recruited and established core team and set up governance structures Established an innovation pipeline, stage gates and the criteria for project progression A defined IP portfolio, 11 Proof of Concept and 4 Co-Development projects directly funded Pipeline of 107 collaborative innovation projects Engagement with 34 company partners Access to wider network of 200 plus potential collaborative companies.